Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.

Medical oncology (Northwood, London, England) - 23 Nov 2021

Nath Arijit, Mitra Soham, Mistry Tanuma, Pal Ranita, Nasare Vilas D

Abstract excerpt

Triple-negative breast cancer (TNBC) is a specific subtype of breast cancer (BC), which shows immunohistochemically negative expression of hormone receptor i.e., Estrogen receptor and Progesterone receptor along with the absence of Human Epidermal Growth Factor Receptor-2 (HER2/neu). In Indian scenario the prevalence of BC is 26.3%, whereas, in West Bengal the cases are of 18.4%. But the rate of TNBC has...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Neoplastic Stem Cells

Share to Phenotype

Share to Signal Transduction

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 34812991
DOI: 10.1007/s12032-021-01610-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.PMID 34812991Read ↗

Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic AdvancementsSemantic proximity Read ↗

Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer.Semantic proximity Read ↗

Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review)Semantic proximity Read ↗

Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC).Semantic proximity Read ↗

Triple negative breast cancer: looking for the missing link between biology and treatments.Semantic proximity Read ↗

New Biomarkers and Treatment Advances in Triple-Negative Breast CancerSemantic proximity Read ↗

Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast CancerSemantic proximity Read ↗

Triple-negative breast cancer and the need for new therapeutic targets.Semantic proximity Read ↗

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategiesSemantic proximity Read ↗

Divide and Conquer—Targeted Therapy for Triple-Negative Breast CancerSemantic proximity Read ↗

Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of researchSemantic proximity Read ↗

Triple-negative breast cancer: unique biology and its management.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.